Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug;89(2):415-417.
doi: 10.1016/j.jaad.2023.04.029. Epub 2023 Apr 23.

Efficacy, safety, and treatment patterns of ruxolitinib 1.5% cream in adult atopic dermatitis: A single center retrospective study

Nicole S Stefanko  1 , Victor L Quan  1 , Raj Chovatiya  2
Affiliations

Efficacy, safety, and treatment patterns of ruxolitinib 1.5% cream in adult atopic dermatitis: A single center retrospective study

Nicole S Stefanko et al. J Am Acad Dermatol. 2023 Aug.
No abstract available

Keywords: atopic dermatitis; eczema; ruxolitinib.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest RC has served as an advisory board member, consultant, and/or investigator for AbbVie, Apogee, Arcutis, Argenx, ASLAN, Beiersdorf, Boehringer Ingelheim, Bristol Myers Squibb, Cara Therapeutics, Dermavant, Eli Lilly and Company, Galderma, Genentech, Incyte, LEO Pharma, L’Oréal, Novan, Inc/EPI Health, Pfizer Inc, Regeneron, Sanofi, and UCB, and speaker for AbbVie, Arcutis, Beiersdorf, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Incyte, LEO Pharma, Novan, Inc/EPI Health, Pfizer Inc, Regeneron, Sanofi, and UCB. NSS and VLQ report no relevant disclosures.

Figures

Figure 1.
Figure 1.
Atopic dermatitis severity by investigator’s global assessment before and after treatment with ruxolitinib 1.5% cream.
See this image and copyright information in PMC

References

    1. Bissonnette R, Call RS, Raoof T, et al. A Maximum-Use Trial of Ruxolitinib Cream in Adolescents and Adults with Atopic Dermatitis. Am J Clin Dermatol. May 2022;23(3):355–364. doi: 10.1007/s40257-022-00690-3 - DOI - PMC - PubMed
    1. Kim BS, Howell MD, Sun K, et al. Treatment of atopic dermatitis with ruxolitinib cream (JAK1/JAK2 inhibitor) or triamcinolone cream. J Allergy Clin Immunol. Feb 2020;145(2):572–582. doi: 10.1016/j.jaci.2019.08.042 - DOI - PubMed
    1. Kim BS, Sun K, Papp K, Venturanza M, Nasir A, Kuligowski ME. Effects of ruxolitinib cream on pruritus and quality of life in atopic dermatitis: Results from a phase 2, randomized, dose-ranging, vehicle- and active-controlled study. J Am Acad Dermatol. Jun 2020;82(6):1305–1313. doi: 10.1016/j.jaad.2020.02.009 - DOI - PubMed
    1. Papp K, Szepietowski JC, Kircik L, et al. Efficacy and safety of ruxolitinib cream for the treatment of atopic dermatitis: Results from 2 phase 3, randomized, double-blind studies. J Am Acad Dermatol. Oct 2021;85(4):863–872. doi: 10.1016/j.jaad.2021.04.085 - DOI - PubMed